News

Public · Published

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

Arcturus Therapeutics, a messenger RNA medicines company developing liver and respiratory treatments, said it will release its third quarter 2026 financial results after the market close on Thursday, November 5, 2026, and host a conference call and webcast at 4:30 pm Eastern Time that day.

Published:

Updated:

What happened

Arcturus Therapeutics, a messenger RNA medicines company developing liver and respiratory treatments, said it will release its third quarter 2026 financial results after the market close on Thursday, November 5, 2026, and host a conference call and webcast at 4:30 pm Eastern Time that day.

Confirmed

Global impact / market context

Quarterly results show how much cash Arcturus has and how much it spends on research, which matters because drug developers often lose money while testing treatments. The update may also reveal progress on its liver and respiratory programs and partnerships, helping investors judge whether it can fund development without raising more money.

Analyst inference

Arcturus is a small messenger RNA developer whose shares can swing on trial news and financing needs. Its collaborations with Thermo Fisher, BARDA and ARCALIS, a Japanese joint venture, support manufacturing and pandemic work. The earnings call gives investors a scheduled moment to reassess spending, cash runway and pipeline progress.

Analyst inference

What to watch

  1. The company will release results after the market close and hold a call at 4:30 pm Eastern Time on November 5, 2026, so investors will hear management discuss the quarter. Confirmed
  2. Listen for details on trial timelines and partnership funding, which would show whether Arcturus can advance liver and respiratory programs without raising more money. Proposed
  3. Watch cash and spending figures, because a drug developer that uses cash faster than expected may need to sell shares, which can reduce the value of existing holdings. Analyst inference

Evidence

  • Original source link unavailable